Christopher Brightling on tezepelumab in patients with moderate-to-severe uncontrolled asthma

from The Lancet Respiratory Medicine in conversation with · host The Lancet Respiratory Medicine

Christopher Brightling discusses the effect of blocking thymic stromal lymphopoietin (TSLP) with tezepelumab in patients with moderate-to-severe uncontrolled asthma. Read the full article: https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00226-5/fulltext Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Episode metadata supplied by the publisher feed · Published Jul 10, 2021

Embed this episode

Attribution link and audio player

NOW PLAYING

Christopher Brightling on tezepelumab in patients with moderate-to-severe uncontrolled asthma

0:00 13:17

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Lancet Respiratory Medicine in conversation with?

This episode is 13 minutes long.

When was this The Lancet Respiratory Medicine in conversation with episode published?

This episode was published on July 10, 2021.

Can I download this The Lancet Respiratory Medicine in conversation with episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!